Shanghai Ruijikang Biotechnology

Shanghai Ruijikang Biotechnology is a pioneering biopharmaceutical company dedicated to the development of next-generation, off-the-shelf cell therapies. The company utilizes a proprietary induced pluripotent stem cell (iPSC) platform to create standardized, scalable immune cell products, including iPSC-derived natural killer (iNK) and T (iT) cells. Founded by Dr. Frank Fan, the former Chief Scientific Officer of Legend Biotech, Ruijikang leverages deep expertise in chimeric antigen receptor (CAR) engineering and stem cell biology. Its therapeutic pipeline is primarily focused on addressing unmet needs in oncology, targeting both hematological malignancies and refractory solid tumors. By shifting from autologous to allogeneic models, the company aims to significantly reduce manufacturing costs and improve patient access to life-saving treatments. Ruijikang is backed by prominent venture capital firms and operates state-of-the-art research and development facilities in Shanghai.